Source: International Congress 2016 – In-patient and out-patient COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Federico Saibene (Milan, Italy), Federico Saibene, Gregorino Paone, Luigi Lanata, Giovanni Puglisi, Barbara Moscatelli, Renato Delli Colli. Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids. Eur Respir J 2016; 48: Suppl. 60, 544

Member's Comments

No comment yet.

Related content which might interest you: A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Impact of mucolytic treatment on COPD exacerbations Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Effect of low dose theophylline as adjunct in treatment of COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE) Source: International Congress 2016 – Pharmacological management of COPD Year: 2016